Semaglutide, Wegovy, and tirzepatide became blockbuster drugs because of what they do for diabetes and obesity.
But something is changing.
New prescribing data, combined with a real shift in pharmaceutical marketing, shows GLP-1 drugs are increasingly being used and sold not just as medical treatment, but as weight-loss and lifestyle products.
And the numbers back it up.
Key findings
- 1.1 million U.S. adults received a GLP-1 prescription with no diabetes or obesity diagnosis documented in their record.
- GLP-1 prescribing among people without a documented qualifying condition rose roughly 13 to 15-fold between 2021 and 2025.
- 35.1% had a normal BMI on record.
- 85.5% were women.
- Eating-disorder history showed up at roughly six times the rate seen in the comparison group.
- Novo Nordisk and other manufacturers are leaning harder into consumer weight-loss language instead of strictly clinical obesity messaging.
GLP-1 marketing is changing
Novo Nordisk’s marketing for Wegovy has drifted away from clinical language.
Instead of leading with obesity, chronic disease, and long-term weight management, recent campaigns lean on phrases like “Live lighter” and “Summer Glow Up.”
STAT News reporting also described a broader shift toward calling people on these drugs “customers” instead of “patients.”
The medicine did not change.
The pitch did.
A treatment for obesity implies a diagnosed medical condition managed by a doctor. A lifestyle product sounds different. It suggests someone might want the drug simply to lose weight, look a certain way, or feel a certain way.
That distinction matters more as GLP-1 drugs push deeper into mainstream culture.
GLP-1 off-label prescribing has increased dramatically
Researchers analyzing the COSMOS database looked at roughly 90 million U.S. adults without a documented qualifying condition for GLP-1 treatment between 2021 and 2025.
The drugs studied included:
Roughly 1.1 million adults received a GLP-1 prescription despite no diabetes or obesity diagnosis documented in their medical record.
The prescribing rate climbed from about 0.1% in 2021 to about 1.5% in 2025.
That’s a 13 to 15-fold increase.
This is not a minor shift in prescribing behavior. It suggests the population using GLP-1 drugs is expanding well beyond the group these medications were originally marketed for.
More than one-third had a normal BMI
One of the most striking findings: 35.1% of recipients had a normal BMI recorded.
That doesn’t automatically mean the prescription was inappropriate. Medical records are imperfect. Some people previously had obesity, lost weight before the study period, got care elsewhere, or had relevant diagnoses that weren’t properly captured. The researchers specifically warned against treating a missing diagnosis as proof no legitimate medical reason existed.
Still, the trend is hard to ignore. A substantial share of GLP-1 prescriptions are now going to people whose available records don’t show the traditional obesity or diabetes diagnoses tied to these drugs.
GLP-1 use and eating-disorder history
Another finding deserves attention.
People receiving GLP-1 prescriptions without a documented qualifying condition had a sixfold higher rate of recorded eating-disorder history.
The rates: 1.8% versus 0.3%.
That doesn’t prove GLP-1 drugs caused or worsened an eating disorder. But these medications strongly suppress appetite and food intake, which makes this a population researchers and prescribers need to keep studying closely.
As GLP-1 drugs become more common for cosmetic or lifestyle-driven weight loss, the profile of who’s seeking them may shift too.
Are GLP-1 drugs becoming lifestyle drugs?
Culturally and commercially, increasingly yes.
The first major GLP-1 era centered on diabetes. The second centered on obesity treatment. We may be entering a third phase:
GLP-1 drugs as consumer weight-management tools.
That shift could reshape:
- how pharmaceutical companies advertise
- how telehealth companies market treatment
- who asks doctors for a prescription
- how insurers decide what to cover
- how regulators view promotional claims
- how society thinks about medically assisted weight loss
A few years ago, taking a weekly injectable medication to lose ten or fifteen pounds would have seemed unusual. Today the idea barely raises an eyebrow. That’s a remarkable cultural shift in a short window of time.
The GLP-1 pipeline is only getting bigger
The lifestyle-drug shift isn’t happening in isolation. It’s landing at the same time the GLP-1 pipeline itself is expanding fast, which is part of why the marketing and the prescribing numbers are moving together.
Beyond the three original drugs studied above, a wave of next-generation GLP-1 and multi-agonist compounds is now in research or later-stage development, including retatrutide, orforglipron (an oral GLP-1), Cagri-Sema, amycretin, mazdutide, pemvidutide, and survodutide. Each takes a different mechanistic angle on the same appetite and metabolic pathways, and each page on this site breaks down what’s actually been published on it versus what’s just circulating online.
More entrants means more marketing budgets competing for the same “customers,” which is likely to accelerate the lifestyle-drug framing rather than slow it down.
Does this mean GLP-1 drugs don’t work?
No.
This research doesn’t change the strong clinical-trial evidence supporting GLP-1 drugs for their approved populations. Semaglutide and tirzepatide have produced substantial weight loss in large randomized clinical trials.
The real question here is different: what happens when highly effective obesity medications increasingly move beyond obesity treatment?
That’s where medicine, lifestyle culture, telehealth, advertising, and pharmaceutical economics start colliding.
Frequently asked questions
What is off-label GLP-1 use?
Off-label prescribing happens when an approved drug is prescribed for a use or patient population outside its specific FDA-approved labeling. It’s legal and common across U.S. medicine.
Can someone with a normal BMI take a GLP-1 drug?
A normal BMI on record doesn’t automatically prove a GLP-1 prescription was inappropriate. BMI is an imperfect measurement, and individual medical histories can include factors not visible in a database. The study simply shows GLP-1 prescribing among people without a documented qualifying condition is rising fast.
Are GLP-1 drugs becoming lifestyle drugs?
The evidence suggests they’re increasingly being marketed and used that way, even though they remain prescription medications with specific FDA-approved indications.
Does this research show GLP-1 drugs are unsafe?
No. The study looked at prescribing patterns, not whether GLP-1 treatment was safe or effective in every subgroup identified.
Bottom line
Two separate trends point in the same direction.
Pharmaceutical companies are leaning harder into consumer-friendly language around GLP-1 weight loss. At the same time, prescribing data shows a dramatic increase in GLP-1 use among Americans without a documented diagnosis of obesity or diabetes.
Neither finding proves those prescriptions were inappropriate. Neither changes the clinical evidence supporting GLP-1 medications for approved populations.
But together they suggest something important:
GLP-1 drugs are no longer functioning only as obesity medications.
They’re becoming medical treatments, weight-management tools, and consumer lifestyle products at the same time. That may turn out to be one of the biggest shifts of the entire GLP-1 era.
For a full look at how we source and label claims like the ones in this piece, see our evidence standards page. For the individual research profiles on any compound mentioned here, browse the linked peptide and blend pages above.
Sources
- Chen, Elaine. “GLP-1 drugs are being marketed as lifestyle drugs now, not just obesity treatment.” STAT News, September 28, 2026.
- Peer-reviewed study using the COSMOS/Epic Systems research database (~90 million U.S. adults, 2021-2025), published in Obesity.
